These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3857184)

  • 21. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L
    J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
    Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
    Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
    Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Off label drug use in adult patients treated by anticancer chemotherapy].
    Levêque D; Michallat AC; Schaller C; Ranc M
    Bull Cancer; 2005 May; 92(5):498-500. PubMed ID: 15932813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy.
    Pütz G; Schmah O; Eckes J; Hug MJ; Winkler K
    Med Hypotheses; 2009 Apr; 72(4):393-7. PubMed ID: 19147297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curative and palliative aspects of regional chemotherapy in combination with surgery.
    Müller H; Hilger R
    Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD
    Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body surface area in normal-weight, overweight, and obese adults. A comparison study.
    Verbraecken J; Van de Heyning P; De Backer W; Van Gaal L
    Metabolism; 2006 Apr; 55(4):515-24. PubMed ID: 16546483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting transcription factors for cancer therapy.
    Frank DA
    IDrugs; 2009 Jan; 12(1):29-33. PubMed ID: 19127502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body surface area capping may not improve cytotoxic drugs tolerance.
    Bouleftour W; Viard A; Mery B; Chaux R; Magne N; Simoens X; Rivoirard R; Forges F
    Sci Rep; 2021 Jan; 11(1):2431. PubMed ID: 33510207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Body Surface Area Formulas for the Calculation of the Chemotherapy Dosage].
    Hatahira H; Iguchi K; Sasaoka S; Motooka Y; Hasegawa S; Naganuma M; Fukuda A; Ohmori T; Yoshida T; Mogushi K; Nakamura M
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):1011-1015. PubMed ID: 29138378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
    Felici A; Verweij J; Sparreboom A
    Eur J Cancer; 2002 Sep; 38(13):1677-84. PubMed ID: 12175683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The overdose of drugs in Japan.
    Fukushima M
    Nature; 1989 Dec 21-28; 342(6252):850-1. PubMed ID: 2594079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.